Related Experiment Videos
Indications of plasma exchanges for systemic vasculitides
Loïc Guillevin1, Christian Pagnoux
1Department of Internal Medicine, Hôpital Avicenne, Université Paris-Nord, Assistance Publique-Hôpitaux de Paris, Bobigny, France. loic.guillevin@avc.ap-hop-paris.fr
Summary
Plasma exchange therapy is crucial for treating various systemic vasculitides, especially when combined with other treatments. This review details its essential role in conditions like HBV-related polyarteritis nodosa and Goodpasture
Area of Science:
- Nephrology
- Rheumatology
- Immunology
Background:
- Systemic vasculitides encompass a group of autoimmune diseases characterized by inflammation of blood vessels.
- Plasma exchange (PE) is an extracorporeal therapy that removes plasma and its components.
- Therapeutic trials have established specific indications for PE in managing these conditions.
Purpose of the Study:
- To review the established indications for plasma exchange in systemic vasculitides.
- To evaluate the efficacy of plasma exchange in conjunction with other therapies.
- To synthesize evidence from major clinical trials regarding PE's role.
Main Methods:
- Review of major therapeutic trials and clinical studies.
- Analysis of treatment protocols involving plasma exchange for systemic vasculitides.
- Synthesis of evidence for specific vasculitic conditions.
Main Results:
- Plasma exchange is essential for HBV-related polyarteritis nodosa, pauci-immune glomerulonephritis, and Goodpasture's syndrome.
- It is effective in HIV/HBV-associated vasculitides when combined with antiretroviral therapy.
- Plasma exchange helps control or attenuate diseases like Wegener's granulomatosis and Churg-Strauss syndrome.
Conclusions:
- Plasma exchange is a vital therapeutic option for numerous systemic vasculitides.
- Its application is optimized when used adjunctively with antiviral or immunosuppressive agents.
- Evidence from trials supports the continued use of plasma exchange in specific vasculitic indications.